Hosted on MSN1mon
OcuTerra’s Phase II diabetic retinopathy trial misses endpoints
OcuTerra Therapeutics has reported that its Phase II DR:EAM clinical trial of selective RGD integrin inhibitor nesvategrast (OTT166) eye drops for patients with diabetic retinopathy (DR ...
BioWorld5d
Integrin α5β1 is target for pulmonary arterial hypertension
Researchers from Morphic Therapeutic Inc. and affiliated organizations published data from a study that aimed to assess the potential of using arginylglycylaspartic acid (RGD) integrins for the ...
pharmaphorum2y
Oxurion craters as failed trial cuts its pipeline down to one
The decision affects THR-687, a pan RGD integrin antagonist for the treatment of diabetic macular oedema (DME), and leaves Oxurion with a single clinical-stage candidate – plasma kallikrein ...
Medscape1mon
A Novel Treatment for Glioblastoma
Integrins are very attractive therapeutic targets in oncology. The anti-tumor mechanisms of integrin-targeting drugs have been validated both in vitroand in vivo. Integrin-targeting drugs are ...
Nature10y
IGFBP-2 inhibits adipogenesis and lipogenesis in human visceral, but not subcutaneous, adipocytes
Both wild-type IGFBP-2 and HBD-mutant IGFBP-2 contain the RGD sequence that allows binding with α5β1 integrin receptors. It has been shown that α5β1 integrin receptor activation leads to FAK ...